Tonix Pharmaceuticals Holding Corp. (TNXP): Price and Financial Metrics
GET POWR RATINGS... FREE!
TNXP Stock Price Chart Interactive Chart >
TNXP Price/Volume Stats
| Current price | $0.62 | 52-week high | $7.71 |
| Prev. close | $0.59 | 52-week low | $0.29 |
| Day low | $0.59 | Volume | 931,593 |
| Day high | $0.64 | Avg. volume | 3,615,604 |
| 50-day MA | $0.86 | Dividend yield | N/A |
| 200-day MA | $0.90 | Market Cap | 38.54M |
Tonix Pharmaceuticals Holding Corp. (TNXP) Company Bio
Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company that develops therapies for disorders of the central nervous system ("CNS"). The Company develops therapies for disorders that include fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD").
Latest TNXP News From Around the Web
Below are the latest news stories about TONIX PHARMACEUTICALS HOLDING CORP that investors may wish to consider to help them evaluate TNXP as an investment opportunity.
Tonix Pharmaceuticals Announces Oral Presentations at the World Vaccine CongressCHATHAM, N.J., March 27, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical and Farooq Nasar, Ph.D., Senior Principal Investigator, both of Tonix Pharmaceuticals, will deliver oral presentations at the World Vaccine Congress, which will be held in Washington D.C., April 3 - 6, 2023. Copies of the Company’s presentations will be available under |
Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership SummitCHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, delivered an oral presentation on March 23, 2023, at the Rare Disease Innovation and Partnership Summit being held as a hybrid event in Philadelphia, Pa. A copy of the presentation is available under the Scientific Presentations |
Tonix Pharmaceuticals Announces Oral Presentation and Poster at the 5th International Congress on Controversies in FibromyalgiaCHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver an oral presentation and the Company will present a poster at the 5th International Congress on Controversies in Fibromyalgia being held March 30-31, 2023 at the Austria Trend Hotel Savoyen Vienna, Vienna, Austria. Copies of the Company’s presentati |
Tonix Pharmaceuticals to Present at the 2023 Virtual March Investor SummitCHATHAM, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Virtual March Investor Summit on Wednesday, March 29, 2023, at 9:00 a.m. ET. Investors interested in arranging a meeting with the Company’s management during the conference should contact the Investor Summit conference coordinator. A webcast of th |
Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership SummitCHATHAM, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, will deliver a presentation at the Rare Disease Innovation and Partnership Summit, which will be held as a hybrid event in Philadelphia, Pa., March 21 - March 23, 2023. A copy of the Company’s presentation will be available under |
TNXP Price Returns
| 1-mo | -11.43% |
| 3-mo | 59.06% |
| 6-mo | 16.06% |
| 1-year | -91.26% |
| 3-year | -97.15% |
| 5-year | -99.99% |
| YTD | 59.06% |
| 2022 | -96.59% |
| 2021 | -47.01% |
| 2020 | -42.31% |
| 2019 | -94.68% |
| 2018 | -93.62% |
Loading social stream, please wait...